FDA Grants Approval for New CAR-T Therapy for Relapsed Lymphoma in 2026
The regulatory landscape for CAR-T cell therapies continues to evolve rapidly in 2026, with the FDA expanding its approvals to include new products and new indications for patients with relapsed or refractory lymphoma. For patients…